{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:33Z","timestamp":1792517853748,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec><jats:title>Background aims<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T-cell therapy shows remarkable efficacy against relapsed\/refractory multiple myeloma (R\/R MM). Nutritional status, assessed by objective indices like the Controlling Nutritional Status (CONUT) and Prognostic Nutritional Index (PNI), influences MM prognosis. However, their predictive value for outcomes following CAR-T therapy in R\/R MM remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of 181 R\/R MM patients receiving CAR-T therapy. Patients were stratified by optimal CONUT (cutoff: 6.5) and PNI (cutoff: 42.75) scores determined via ROC analysis. Associations between CONUT\/PNI and treatment outcomes were investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with low CONUT or high PNI exhibited significantly improved progression-free survival (PFS) and overall survival (OS) compared to their counterparts (high CONUT or low PNI). While objective response rates (ORR) were high overall (approximately 90\u201395%), they did not differ significantly between CONUT or PNI subgroups. Importantly, low CONUT or high PNI was associated with faster hematopoietic recovery (red blood cells, hemoglobin, platelets, neutrophils, CD4+, CD8\u202f+\u202fT-cells), lower incidence of prolonged hematologic toxicity (PHT), and higher peak CAR transgene levels. No significant differences were observed in cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) severity between subgroups. Multivariate analysis confirmed high CONUT as an independent risk factor for inferior PFS and OS, while low PNI was an independent risk factor for inferior PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study establishes pretreatment CONUT and PNI as significant prognostic predictors for R\/R MM patients undergoing CAR-T therapy. Patients with low CONUT or high PNI experience superior long-term survival outcomes, potentially linked to enhanced hematopoietic recovery and CAR-T cell expansion. These findings underscore the importance of nutritional assessment in prognostication and may guide future strategies to optimize CAR-T outcomes in R\/R MM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnut.2025.1654407","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:17:23Z","timestamp":1759292243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Nutritional status indices on the prognosis of patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2023-191911","article-title":"Phase 3 randomized study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): primary results of the Perseus trial","volume":"142","author":"Sonneveld","year":"2023","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb 2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-Centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/advances\/nmaa102","article-title":"Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with Cancer: a systematic review","volume":"12","author":"Kheirouri","year":"2021","journal-title":"Adv Nutr"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-016-2696-0","article-title":"The pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study","volume":"16","author":"Toyokawa","year":"2016","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/jpen.2321","article-title":"Value of the controlling nutritional status score in predicting the prognosis of patients with lung cancer: a multicenter, retrospective study","volume":"46","author":"Liu","year":"2022","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"656741","DOI":"10.3389\/fcell.2021.656741","article-title":"Prognostic nutritional index (PNI) in patients with breast Cancer treated with Neoadjuvant chemotherapy as a useful prognostic Indicator","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1213255","DOI":"10.3389\/fnut.2023.1213255","article-title":"Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors","volume":"10","author":"Yan","year":"2023","journal-title":"Front Nutr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12935-020-01535-x","article-title":"Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis","volume":"20","author":"Luan","year":"2020","journal-title":"Cancer Cell Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jcyt.2024.03.481","article-title":"Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy","volume":"26","author":"Cheng","year":"2024","journal-title":"Cytotherapy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1517223","DOI":"10.3389\/fonc.2025.1517223","article-title":"Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis","volume":"15","author":"Jin","year":"2025","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00277-019-03844-2","article-title":"Clinical impact of the CONUT score in patients with multiple myeloma","volume":"99","author":"Okamoto","year":"2020","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/life15020289","article-title":"Optimizing autologous stem cell transplantation in multiple myeloma: the significance of pre-transplant controlling nutritional status score","volume":"15","author":"\u00d6zkan","year":"2025","journal-title":"Life"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10143-023-02248-1","article-title":"C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients","volume":"47","author":"Zuo","year":"2023","journal-title":"Neurosurg Rev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/10428194.2021.2020777","article-title":"Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma","volume":"63","author":"Nakamura","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1080\/10428194.2020.1749608","article-title":"The prognostic value of the controlling nutritional status score in patients with multiple myeloma","volume":"61","author":"Kamiya","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00277-020-04262-5","article-title":"Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma","volume":"99","author":"Matsukawa","year":"2020","journal-title":"Ann Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/nu15194210","article-title":"Nutritional status indices and monoclonal Gammopathy of undetermined significance risk in the elderly population: findings from the National Health and nutrition examination survey","volume":"15","author":"Li","year":"2023","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ni.3754","article-title":"Nutrition, inflammation and cancer","volume":"18","author":"Zitvogel","year":"2017","journal-title":"Nat Immunol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3389\/fimmu.2018.01055","article-title":"Changes in nutritional status impact immune cell metabolism and function","volume":"9","author":"Alwarawrah","year":"2018","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41430-025-01565-6","article-title":"The dynamic effects of nutritional status on chemotherapy-related toxicity in patients with non-Hodgkin's lymphoma","volume":"79","author":"Zhou","year":"2025","journal-title":"Eur J Clin Nutr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12957-017-1226-0","article-title":"Impact of nutritional status in the era of FOLFOX\/FIRI-based chemotherapy","volume":"15","author":"Okada","year":"2017","journal-title":"World J Surg Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"997589","DOI":"10.3389\/fimmu.2022.997589","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1019548","DOI":"10.3389\/fimmu.2022.1019548","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1007\/s10238-023-01232-9","article-title":"Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy","volume":"23","author":"Cheng","year":"2023","journal-title":"Clin Exp Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/life14040461","article-title":"Role of immune cells and immunotherapy in multiple myeloma","volume":"14","author":"Radhakrishnan","year":"2024","journal-title":"Life"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci Immunol"},{"key":"ref40","first-page":"38","article-title":"CONUT: a tool for controlling nutritional status. First validation in a hospital population","volume":"20","author":"Ignacio de Ulibarri","year":"2005","journal-title":"Nutr Hosp"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","journal-title":"Am J Surg"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1654407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:17:24Z","timestamp":1759292244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1654407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":41,"alternative-id":["10.3389\/fnut.2025.1654407"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1654407","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1654407"}}